The amplification of ERBB2 serves as a predictive and prognostic marker and is typically associated with tumor aggressiveness (high-grade tumor mitotic count), resistance to chemotherapy, distant metastases, and adverse clinical outcomes [12]. This evidence concerns the gene ERBB2 and neoplasm.